Market Overview:
The global liposomal mifamurtide market is expected to register a CAGR of xx% during the forecast period 2018-2030. The growth in this market can be attributed to factors such as rising incidence of cancer, increasing demand for targeted therapies, and technological advancements in the field of liposomal drug delivery. Based on type, the global liposomal mifamurtide market is segmented into brands and generic. The brands segment is expected to account for a larger share of the market during the forecast period. This can be attributed to factors such as patent protection for key players in this segment and higher prices associated with branded products. However, generic drugs are anticipated to grow at a faster rate than branded products during the forecast period owing to their lower prices and easy availability through online pharmacies and retail stores. On basis of application, hospital accounted for majority share of Liposomal Mifamurtide Market In 2017 And Is Expected To Grow At A Cagr Of ____%. Drug store Segment Is Expected To Grow At A Higher Rate Than Hospital Segment During The Forecast Period ____%. This Can Be Attributed To Rising Prevalence Of Cancer And Increasing Demand For Targeted Therapies Which Are Available Mostly Through Hospitals And Specialty Clinics ____%.
Product Definition:
Liposomal Mifamurtide is a liposomal formulation of the chemotherapeutic agent mifamurtide. It is indicated for the treatment of high-grade, resectable osteosarcoma in pediatric and young adult patients.
Brands:
Brands, their usage and growth factor in Liposomal Mifamurtide market? Branded products are the ones that have a brand name or registered trademark. The main function of these brands is to give consumers a feeling of security as they can rely on them for quality and safety. They also add value to the product by increasing its shelf life which thereby increases its utility in the market.
Generic:
Mifamurtide is a generic name for the active ingredient in Liposomal Mifamurtide. It is also known as palmitoyl tetrapeptide and it's chemical structure consists of 16-aminolevulinic acid (16-ALA). The product has been studied extensively in preclinical models for its ability to reduce inflammation, improve cardiovascular function, and prevent diabetes.
Application Insights:
Drug store was the largest application segment in 2017 and is expected to maintain its lead over the forecast period. Mifamurtide-based drugs are used for treating various medical conditions, such as diabetes, cardiovascular diseases, cancer and respiratory problems. The growing geriatric population across the world is anticipated to drive demand for medicines that can help prevent or treat illnesses related to aging. This will further fuel product demand in drug stores over the coming years.
The hospital segment is also poised to witness significant growth owing to rising awareness about effective treatment of life-threatening conditions through liposomal mifamurtide therapy among healthcare professionals and patients worldwide. In addition, increasing number of hospitals offering clinical trials on a patient by patient basis will boost market growth during the forecast period.
The others segment includes personal care products.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to high product penetration, favorable reimbursement policies, and increasing healthcare expenditure in this region. In addition, rising obesity levels are also expected to drive demand for mifamurtide products over the forecast period.
Asia Pacific is anticipated to witness significant growth over the coming years owing to untapped opportunities and rapidly growing economy of developing countries such as China and India. Moreover, these countries have a large geriatric population base that requires long-term treatment with liposomal drugs due to their poor response or intolerance towards standard therapies observed during clinical trials performed decades ago for initial approval of these products by regulatory agencies like FDA & EMEA (European Medicines Agency).
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is expected to drive the demand for novel and innovative therapies such as liposomal Mifamurtide, thereby propelling the growth of the market.
- Rising awareness about cancer treatments: There is a growing awareness among people about various types of cancers and their treatments. This is likely to boost the demand for liposomal Mifamurtide in the coming years.
- Technological advancements in drug delivery systems: The development of novel drug delivery systems has revolutionized how drugs are administered to patients, thus providing a major impetus to the growth of this market. Liposomal Mifamurtide represents one such innovation that is likely to gain traction in the coming years owing its superior efficacy and safety profile over traditional chemotherapy regimens used for treating various forms of cancers including osteosarcoma, Ewing’s sarcoma, and lymphoma etcetera . 4) Growing preference for targeted therapies over traditional chemotherapy regimens: A growing number of oncologists are preferring targeted therapies over traditional chemotherapy regimens due to their better efficacy and safety profiles across a range tumor types . Liposomal Mifamurtide belongs to this categoryof targeted therapeuticsand hence holds immense potentialto tap into this rapidly growing segment5) Rising healthcare expenditure worldwide: A significant rise in healthcare expenditure worldwide has led medical professionals & payers alike
Scope Of The Report
Report Attributes
Report Details
Report Title
Liposomal Mifamurtide Market Research Report
By Type
Brands, Generic
By Application
Hospital, Drugs Store
By Companies
Takeda
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
187
Number of Tables & Figures
131
Customization Available
Yes, the report can be customized as per your need.
Global Liposomal Mifamurtide Market Report Segments:
The global Liposomal Mifamurtide market is segmented on the basis of:
Types
Brands, Generic
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Store
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Takeda
Highlights of The Liposomal Mifamurtide Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Brands
- Generic
- By Application:
- Hospital
- Drugs Store
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Liposomal Mifamurtide Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Liposomal Mifamurtide is a medication that is used to treat multiple myeloma. It works by stopping the growth of cancer cells in the body.
Some of the key players operating in the liposomal mifamurtide market are Takeda.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Liposomal Mifamurtide Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Liposomal Mifamurtide Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Liposomal Mifamurtide Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Liposomal Mifamurtide Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Liposomal Mifamurtide Market Size & Forecast, 2020-2028 4.5.1 Liposomal Mifamurtide Market Size and Y-o-Y Growth 4.5.2 Liposomal Mifamurtide Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Brands
5.2.2 Generic
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drugs Store
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Liposomal Mifamurtide Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Liposomal Mifamurtide Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Brands
9.6.2 Generic
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drugs Store
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Brands
10.6.2 Generic
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drugs Store
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Brands
11.6.2 Generic
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drugs Store
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Brands
12.6.2 Generic
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drugs Store
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Brands
13.6.2 Generic
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drugs Store
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Liposomal Mifamurtide Market: Competitive Dashboard
14.2 Global Liposomal Mifamurtide Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Takeda